The Bayh-Dole Act, enacted in 1980, gives NIH certain "march-in" rights to compel drug patent-holders to grant licenses to other manufacturers under certain circumstances. Recently, three Fabry disease patients have been petitioning NIH to exercise its Bayh-Dole march-in rights to demand that Genzyme allow other firms to make Fabrazyme — currently the only effective treatment for the disease — after contamination problems interrupted production at Genzyme's only manufacturing facility in 2009, which caused a shortage of the drug.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.